No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HOOK HOOKIPA Pharma
- 0.706
- -0.007-1.02%
Close Jun 18 16:00 ET
- 0.730
- +0.024+3.37%
Post 18:57 ET
69.88MMarket Cap-1471P/E (TTM)
0.755High0.700Low339.14KVolume0.720Open0.714Pre Close247.56KTurnover0.67%Turnover RatioLossP/E (Static)98.95MShares1.13052wk High0.67P/B35.95MFloat Cap0.41052wk Low--Dividend TTM50.91MShs Float20.000Historical High--Div YieldTTM7.69%Amplitude0.410Historical Low0.729Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Keybanc rai
HOOKIPA Pharma Is Maintained at Buy by HC Wainwright & Co.
HOOKIPA Pharma Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Raises Target Price to $6
H.C. Wainwright analyst Arthur He CFA maintains $HOOKIPA Pharma(HOOK.US)$ with a buy rating, and adjusts the target price from $5 to $6.According to TipRanks data, the analyst has a success rate of 53
Express News | HOOKIPA Pharma Inc. : H.c. Wainwright Raises Target Price to $6 From $5
HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-
Express News | HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
Comments
$HOOKIPA Pharma(HOOK.US$
Up down up down, these shorties will never let us live in peace 🤬🤬🤬
Up down up down, these shorties will never let us live in peace 🤬🤬🤬
$HOOKIPA Pharma(HOOK.US$ @Trytosaveabit
Why is this stock doing so bad? I mean for a clinical stage companythey are even profitable at this quarter means their product must be at least good right ?
Why is this stock doing so bad? I mean for a clinical stage companythey are even profitable at this quarter means their product must be at least good right ?
1
$HOOKIPA Pharma(HOOK.US$ HOOKIPA Pharma Announces Phase 2 Results For HB-200 Combined With Pembrolizumab In HPV16+ Head And Neck Cancer
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed OR...
Benzinga· 1 min ago
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab
In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed OR...
4
2
$HOOKIPA Pharma(HOOK.US$
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). N...
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). N...
8
$HOOKIPA Pharma(HOOK.US$ First though there is to be additional data come out of the ASCO June 4th! Also Researchers intend to present data from investigator initiated trial of HB-200 W/Chemo, on June 3RD! And now to what i wanted to share from my notes that i took in Janu...
17
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg